Clinical trials: Neoplasms, Germ Cell and Embryonal
Neuroblastoma
Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00002802
- Testing
- carboplatin, cisplatin, cyclophosphamide
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Melanoma (Skin)
Boron Neutron Capture Therapy in Treating Patients With Stage III Melanoma
RATIONALE: Boron neutron capture therapy may selectively kill tumor cells without harming normal tissue. PURPOSE: Phase I trial to study the effectiveness of boron neuron capture therapy in treating patients with stage III…
- Trial name
- NCT00002781
- Testing
- boronophenylalanine-fructose complex
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Beth Israel Deaconess Medical Center
Glioblastoma
Study With Nelfinavir and Combined Radiochemotherapy for Glioblastoma
The objectives of the trial are: To assess safety, tolerability and activity of nelfinavir given neo-adjuvant and concomitant to chemoradiotherapy with temozolomide in patients with a newly diagnosed glioblastoma multiforme.
- Trial name
- NCT00694837
- Testing
- nelfinavir
- Where
- Netherlands
- Volunteers
- 6 people
- Sponsor
- Maastricht Radiation Oncology
Non-small Cell Lung Cancer, Gastric Carcinoma
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are.
- Conditions
- Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma
- Trial name
- NCT04254107
- Testing
- SEA-TGT, sasanlimab, brentuximab vedotin
- Where
- 36 sites in United States, Canada and 4 more
- Volunteers
- 133 people
- Sponsor
- Seagen Inc.
Melanoma Stage III, Melanoma Stage IV
A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma
There are in total 3 cohorts. Cohort A: 16 patients will receive a daily dose of 80mg regorafenib up until progressive disease, unacceptable toxicity or withdrawal of consent.
- Trial name
- RegoMel (NCT05370807)
- Testing
- Regorafenib 40 MG Oral Tablet, Triplet therapy
- Where
- Belgium
- Volunteers
- 48 people
- Sponsor
- Universitair Ziekenhuis Brussel
Gestational Trophoblastic Disease, Gestational Trophoblastic Neoplasia
A Feasibility Window Study of Pembrolizumab Prior to Second Evacuation for Post-molar Gestational Trophoblastic Neoplasia
Gestational Trophoblastic Diseases (GTD) are a variety of rare, pregnancy related cell multiplication disorders of cells of the placenta which can range from pre-cancerous growths to more serious lesions that can spread to nearby…
- Conditions
- Gestational Trophoblastic Disease, Gestational Trophoblastic Neoplasia, Gestational Trophoblastic Tumor, Recurrent
- Trial name
- NCT05635344
- Testing
- Pembrolizumab
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Imperial College London
Glioma
Imaging Malignant Glioma With 68Ga-DOTATOC PET/CT
The purpose of this study is to characterize tumour uptake of somatostatin analog 68Ga-DOTATOC in patients with either primary or recurrent malignant glioma.
- Trial name
- DOTAGLI (NCT01460706)
- Testing
- [68Ga]DOTATOC
- Where
- Finland
- Volunteers
- 30 people
- Sponsor
- Turku University Hospital
Glioma, Anaplastic Astrocytoma
Dendritic Cell Vaccine for Patients With Brain Tumors
The main purpose of this study is to evaluate the most effective immunotherapy vaccine components in patients with malignant glioma.
- Conditions
- Glioma, Anaplastic Astrocytoma, Anaplastic Astro-oligodendroglioma, Glioblastoma
- Trial name
- NCT01204684
- Testing
- autologous tumor lysate-pulsed DC vaccination, Tumor lysate-pulsed DC vaccination+0.2% resiquimod, Tumor-lysate pulsed DC vaccination +adjuvant polyICLC
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Melanoma (Skin Cancer)
Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma
This is a single-arm, open-label, single-center, Phase II exploratory clinical study evaluating the efficacy, safety, and tolerability of neoadjuvant pucotenlimab combined with lenvatinib and temozolomide in patients with…
- Trial name
- TRIUMPH-AM (NCT07501104)
- Testing
- Neoadjuvant Pucotenlimab+Lenvatinib+Temozolomide
- Volunteers
- 30 people
- Sponsor
- Shanghai Zhongshan Hospital
Melanoma, Non-Small Cell Lung Cancer
GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients
This study is a dose escalation of GR-MD-02 with the standard therapeutic dose of pembrolizumab in patients with advanced melanoma, non-small cell lung cancer, and head and neck squamous cell cancer.
- Conditions
- Melanoma, Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT02575404
- Testing
- GR-MD-02, Pembrolizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Providence Health & Services
Glioma, Glioblastoma Multiforme
Blood and Cerebrospinal Fluid Metabolomic Profile in Glioma Patients
This is an exploratory, non-interventional and translational clinical study. The aim of this study is to analyze blood and cerebrospinal fluid metabolomic profile in glioma patients.
- Trial name
- NCT03865355
- Testing
- Non- interventional
- Where
- Russia
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Novosibirsk State University
Glioma
Evaluation of the Use of a Method "Radiomics" for DOPA PET in Gliomas
: The evaluation of gliomas in imaging represents a real challenge today, at the initial diagnosis, for therapeutic planning or follow-up treatment of these lesions.
- Trial name
- RADDOPAG-2 (NCT06472440)
- Where
- France
- Volunteers
- 1,000 people
- Sponsor
- Central Hospital, Nancy, France
Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors
This phase I/II trial studies the side effects and best dose of adavosertib and irinotecan hydrochloride in treating younger patients with solid tumors that have come back (relapsed) or that have not responded to standard therapy…
- Conditions
- Central Nervous System Embryonal Tumor With Rhabdoid Features, Central Nervous System Embryonal Tumor, Not Otherwise Specified, Central Nervous System Ganglioneuroblastoma, Embryonal Tumor With Multilayered Rosettes, C19MC-Altered
- Trial name
- NCT02095132
- Testing
- Adavosertib, Irinotecan Hydrochloride
- Where
- 24 sites in United States, Canada
- Volunteers
- 76 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Vaccine Therapy, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: Vaccines made from peptides may help the body build an effective immune response to kill tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either…
- Trial name
- NCT01222221
- Testing
- glioblastoma multiforme multipeptide vaccine IMA950, sargramostim, temozolomide
- Where
- 7 sites in United Kingdom
- Volunteers
- 45 people
- Sponsor
- Cancer Research UK
Oligoastrocytoma, Astrocytoma
Neural Basis of Language Processing
According to the O.M.S. Classification, grade 2 glioma is a pre-cancerous lesion, slowly progressive, infiltrating the central nervous system, mainly affecting young adults.
- Conditions
- Oligoastrocytoma, Astrocytoma, Oligodendroglioma
- Trial name
- BNL (NCT02903784)
- Testing
- fMRI, tractography, neuropsychological examination
- Volunteers
- 63 people
- Sponsor
- University Hospital, Montpellier
Intraocular Melanoma, Melanoma (Skin)
Vaccine Therapy in Treating Patients With Metastatic Melanoma
RATIONALE: Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill melanoma cells.
- Trial name
- NCT00334776
- Testing
- MART-1 antigen, gp100:209-217(210M) peptide vaccine, therapeutic autologous dendritic cells
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- University of Southern California
Glioma, Low-grade Glioma
Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG
The purpose of this study is to see if 18F-Fluciclovine (Axumin®) is useful and safe in the management of children with Low Grade Gliomas (LGG).
- Conditions
- Glioma, Low-grade Glioma, Low Grade Glioma of Brain, Glioma, Malignant
- Trial name
- NCT05555550
- Testing
- 18F-Fluciclovine
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Children's Hospital of Philadelphia
Advanced or Inoperable Malignant Melanoma With BRAF Mutation
Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation
An Open Label, Multicenter, Phase I Extension Study of an Oral Cdk Inhibitor P1446A-05 Administered with an Oral BRAF Inhibitor Vemurafenib (Zelboraf®) in Patients with Advanced or Inoperable Malignant Melanoma with BRAF Mutation…
- Trial name
- NCT01841463
- Testing
- P1446A-05, Vemurafenib (Zelboraf®)
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- Piramal Enterprises Limited
Astrocytoma
TVB- 2640 in Combination With Bevacizumab in Patients With First Relapse of High Grade Astrocytoma
Randomized phase 2 study TVB-2640 in combination with Bevacizumab versus Bevacizumab alone.
- Trial name
- NCT03032484
- Testing
- Bevacizumab, TVB-2640
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Melanoma
Ovarian Reserve and Semen Parameters Evolution During Adjuvant Therapy in Melanoma
Prospective multicentric study including women aged 18 to 37 and men aged 18 to 45 during their visit to centers for the study and storage of human sperm and eggs (CECOS).
- Trial name
- MELpreserv (NCT05429138)
- Testing
- biological sampling
- Where
- 12 sites in France
- Volunteers
- 80 people
- Sponsor
- Assistance Publique Hopitaux De Marseille
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.